Tekturna HCT (hydrochlorothiazide and aliskiren)
Title: Tekturna HCT (hydrochlorothiazide and aliskiren)Category: MedicationsCreated: 2/26/2021 12:00:00 AMLast Editorial Review: 2/26/2021 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - February 26, 2021 Category: Cardiology Source Type: news
FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna)
The U.S. Food and Drug Administration (FDA) is warning of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 24, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Noden Pharma Announces FDA Approval of Tekturna (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
DUBLIN, Nov. 15, 2017 /PRNewswire/ -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 15, 2017 Category: Drugs & Pharmacology Source Type: news
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
DUBLIN, Nov. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by t... Biopharmaceuticals, Cardiology, FDA Noden Pharma, Tekturna, aliskiren, Hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 15, 2017 Category: Pharmaceuticals Source Type: news
Valturna (Aliskiren and Valsartan, USP Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 13, 2017 Category: Drugs & Pharmacology Source Type: news
Amturnide (Aliskiren, Amlodipine and Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 30, 2017 Category: Drugs & Pharmacology Source Type: news
Tekturna (Aliskiren Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 28, 2016 Category: Drugs & Pharmacology Source Type: news
Tekturna HCT (Aliskren and Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 28, 2016 Category: Drugs & Pharmacology Source Type: news
Tekamlo (Aliskiren and Amlodipine Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news
PDL BioPharma Buys Novartis Hypertension Drugs
PDL BioPharma commits to equity investment in Noden Pharma for the acquisition of Tekturna and Tekturna HCT (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 25, 2016 Category: Pharmaceuticals Source Type: news
Aliskiren does not benefit heart failure patients with diabetes
Stephen FellerFLORENCE, Italy, May 23 (UPI) -- A hypertension drug thought to benefit heart failure patients with diabetes did not reduce the rate of death during a clinical trial, researchers report. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 23, 2016 Category: Consumer Health News Source Type: news
ATMOSPHERE: Aliskiren Not Superior to Enalapril in HFATMOSPHERE: Aliskiren Not Superior to Enalapril in HF
The negative trial came with a regulatory wrinkle, resulting in three responses being published with the study. The deputy editor admits this was "a bit usual," but so were the circumstances. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 20, 2016 Category: Cardiology Tags: Cardiology News Source Type: news
ATMOSPHERE and the RAS Blockade Ceiling in Heart FailureATMOSPHERE and the RAS Blockade Ceiling in Heart Failure
Dr Pina interviews Prof McMurray about the trial on aliskiren and enalapril in HF and the perils of retrospective subgroup analyses. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2016 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
No benefit from addition of aliskiren to 'gold standard' ACE inhibitor
In one of the largest trials ever conducted in patients who have heart failure with reduced ejection fraction -- a measure of the heart's ability to pump blood -- the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing 'gold standard' therapy, the angiotensin-converting enzyme inhibitor enalapril, researchers reported. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news
News from ACC.16: ATMOSPHERE, Antiarrhythmics for Out-of-Hospital Cardiac Arrest, and More (FREE)
By the Editors
For the past few days, NEJM Journal Watch has been bringing you breaking news from the American College of Cardiology's annual meeting in Chicago. Take a look at the latest:
Aliskiren for Heart Failure:
In the randomized ATMOSPHERE trial, adding the direct renin … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 4, 2016 Category: Primary Care Source Type: news
